Results 151 to 160 of about 17,302 (216)

Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.

open access: yesBlood
Wang ES   +35 more
europepmc   +1 more source

TP53 mutations drive therapy resistance through post-mitochondrial caspase blockade. [PDF]

open access: yesCell Death Dis
Mamdouh AM   +15 more
europepmc   +1 more source

Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape. [PDF]

open access: yesCurr Oncol
Geddes M   +5 more
europepmc   +1 more source

Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy. [PDF]

open access: yesTher Adv Hematol
Yang Z   +19 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy